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1.Abstract: 
 
Objective. Joint hypermobility (JH) and Joint Hypermobility Syndrome (JHS) are often under-
diagnosed and were never specifically assessed in a selected population of chronic low back pain 
(LBP). This study aimed to assess JH and JHS among a population with chronic LBP using the 
Beighton and the Brigthon criteria. 
 
Methods. We conducted a retrospective cross-sectional study based on a prospective data base 
among 143 patients with non-specific chronic LBP. Patients were seen by the same rheumatologist, 
who looked for JH and JHS and took their medical history. Data were analysed using logistic 
regression.  
 
Results. We found a JH prevalence of 33,3% (CI 95% 22.0-44.6) among women and 21,4% (11.7-
31.2) among men, and for JHS, of 37,9% (26.0-49.8) among women and 30,9% (19.7-42.0) among 
men. JH was less frequent among people older than fifty (P < 0.02). JHS was more prevalent among 
Swiss individuals (P < 0.01) and among individuals having a non-manual job (P<0.03) compared to 
there opposites. Patients having an important limitation for daily living activities were four times 
more likely to have JHS. Degenerative spinal disorders were negatively associated with  JH (OR 
0.31 (0.13-0.73) and JHS (OR 0.31 (0.14-0.68).  
 
Conclusion. A high prevalence of joint hypermobility was found in our population. JHS should be 
part of differential diagnosis in individuals with chronic non-specific LBP.
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2.Introduction 
 
2.1 Joint Hypermobility 
 
Joint Hypermobility (JH) used to only be seen as the normal upper end of a Gaussian distribution of 
joint range of movements (1), an opinion that has now changed. In most recent papers, a 
hypermobile joint is considered as one whose range of movement exceeds what is normal (2, 3). 
The prevalence of JH depends on age, gender and ethnicity. It decreases with age, is about three 
times more frequent among women and is seen more often in African and Asians races compared to 
Caucasians (4). The prevalence of JH in Western populations has been shown as high as 10% by 
epidemiological studies and in other populations it has been recorded to be up to 25% (5, 6). 
 
The conventional method to detect JH clinicaly is to apply the Beighton (1973) nine-point scoring 
system as shown on Table 1 (6). A score of four or more out of nine is usually the score accepted to 
diagnose « generalized » JH (4). Other former or less often used scoring systems exist ( i.e. Carter 
and Wilkinson, Hospital del Mar criteria and Rotes-Querol) (7-9). There also is a four item 
questionnaire developed and validated by Hakim and Grahame (10).
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Table 1.   Beighton score (adapted from Grahame et al. Diagnostic criteria of BJHS, The Journal 
of Rheumatology, 2000) 
Illustrations of the Beighton score taken from Alan HAKIM et Rodney GRAHAME, Best 
Practice & Research Clinical Rheumatology Vol. 17, No. 6, pp. 989-1004, 2003  
 
 
 
 
 
 
 
The ability to: 
1. Passively dorsiflex the 5th metacarpophalangeal joint to 90° or more 
2. Oppose the thumb to the volar aspect of the ipsilateral forearm 
3. Hyerextend the elbow to 10° or more 
4. Hyperextend the knee to 10° or more 
5. Place hands flat on the floor without bending the knees 
One point can be acorded to each side, except for point 5. The maximum Total 
is 9 points 
A score of at least 4/9 is enough to diagnose JH or «generalized» JH 
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2.2 Joint Hypermobility Syndrome 
It is important to distinguish simple JH from the Joint Hypermobility Syndrome (JHS).  
JHS was initially described in 1967, as the occurrence of musculoskeletal symptoms in the presence 
of hypermobility in individuals with no other cause explaining those symptoms (1). 
 
JHS is now seen as a frequently overlooked and underdiagnosed multisystemic condition, belonging 
to the group of the heritable disorder of connective tissue (HDCT) (11). It shares overlapping 
features with the other major HDCT like Ehlers-Danlos syndrome (EDS) (12), Marfan syndrome 
(MS) (13, 14) and osteogenesis imperfecta (OI) (4). For some authors, JHS and EDS Hypermobile 
type (former type III) are clinically indistinguishable and considered as one and the same condition 
(2, 15-17). Others (18) call JHS «Benign Joint Hypermobility Syndrome» (BJHS) to denote a 
normal life expectancy and the absence of cardiac and arterial disorders (18) (unlike others HDCT 
like EDS vascular type or MS) (4). 
 
Observation of families shows that the inheritance probably is autosomical dominant (1, 19, 20). 
In 2003, a mutation in a non-collagenous molecule, tenascin-X, was identified in a subgroup of 
patients (mostly women),with JHS and with EDS hypermobile type (21). But the genetics of JHS 
remains poorly understood (19) and no genic or biochemical marker can be used to confirm the 
diagnosis (22).  
 
Therefore, the diagnosis of JHS remains clinical, the accepted and validated (23) diagnosis criteria 
being the1998 revised Brighton criteria (24), illustrated on Table 2. The Brighton criteria consist of 
a set of major and minor criteria. They do not only include hypermobility, but also take into account 
other manifestations of tissue laxity, like skin striae, varicoce veins or myopia (25). These criteria 
have been demonstrated to have excellent specificity (93%) and sensitivity (93%) (24). 
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Table 2.   The revised Brighton crireria (adapted from Grahame et al. Diagnostic criteria of 
BJHS, The Journal of Rheumatology, 2000) 
 
To diagnose JHS are required the presence of: 
- Two major criteria 
- One major and two minor criteria 
- Four minor criteria 
- Only two minor criteria when a first degree relative is unequivocally affected 
JHS is excluded by when Elhers Danlos syndrome (except the hypermobily type) or Marfan 
syndrome are present, as defined by the Ghent (14) and the Villefranche (12) criteria. 
- Criteria Major 1 and Minor 1 are mutually exclusive, as are Major 2 and Minor 2. 
Major criteria 
1. A Beighton score of 4/9 or greater (either currently or historicaly). 
2. Arthralgia for longer than 3 months in 4 or more joints. 
Minor criteria 
1. A Beighton score of 1, 2 or 3/9 (0,1,2 or 3 if aged 50 or older). 
2. Arthralgia in 1-3 joints or back pain for 3 months or longer, the 
presence of spondylolysis / spondylolisthesis. 
3. Dislocation or subluxation in more than one joint, or in one joint on 
more than one occasion. 
4. Soft tissue rheumatism 3 lesions or more (e.g., epicondylitis, 
tenosynovitis, bursitis). 
5. Marfanoid habitus (tall, slim, span/ height ratio > 1.03, upper:lower 
segment ratio < 0,89, arachnodactyly, (+Steinberg / wrist sign). 
6. Abnormal skin: striae, hyperextensibility, thin skin, papyreceous 
scarring. 
7. Eye sign: drooping eyelids or myopia or antimongoloid slant. 
8. Varicose veins or hernia or uterine/rectal prolapse 
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Indeed, a wide range of symptoms and conditions can be associated with JH and JHS. Articular 
symptoms like arthralgia and fractures (26), premature osteoarthritis sometimes leading to 
chondrocalcinosis (27), chondromalacia patellae (28) and temporomandibular joint dysfunctions 
(29) have been reported.  Low bone mass even in pre-menopausal women has also been associated 
with JH (30). 
As a result of intrinsic weakness, or poor tensile strength, abdominal and pelvic viscera, as well as 
any other structure rich in collagen, may be affected (4): Genitourinary prolapse (31), skin striae or 
hyperextensibility (18) can occur. 
 
Gastro-intestinal disturbances, often classified as functional gastro-intestinal disorders can also be 
present (32). Patients with JHS also manifest dysautonomia symptoms like fainting, palpitations or 
orthostatic intolerance more often than the rest of the population (33-35). 
Anxiety disorders like panic attacks, social phobia and agoraphobia also occur, and have been 
significantly associated with JHS by studies from a Spanish team (36, 37). 
 
2.3 Pain 
Pain is the most common symptom (4, 38). Not all patients with JH experiences pain, as shown by 
Bravo and Wolff who did not find arthralgia in 43% of patients with JHS (22). For those who do it 
is often acute, recurrent and evolves into debilitating chronic pain (4, 38). Soft tissue injuries, like 
strains, tears or stress fracture are frequent. This tendency for injuries can be explained by an 
altered collagen, conducting to fragility of tissues like tendons, cartilage, bone and ligament (25) 
and similarly by the lack of proprioception linked with JHS, which probably adds to the likeliness 
of injury and secondary pain by favouring repeated microtrauma and prolonged abnormal joint 
positions (39-41). 
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Knowing this tendency for pain and injury, it is not surprising that a high prevalence of JHS is 
found in general rheumatology clinics. In this population, Grahame et al. (42) reported a prevalence 
of 46% among women and 31% among men in London, Bravo et al. (22) found a prevalence of 
35% in Chile. The prevalence of JHS in the general population is currently unknown (4). 
 
2.4 Low Back Pain and Hypermobility 
2.4.1 Low Back Pain 
Low back pain (LBP) consists of pain localised between the 12th rib and the inferior gluteal folds, 
acompaigned or not by leg pain. LBP is a very prevalent condition,  the majority of cases being 
non-specific and self-limiting. Still, a small percentage of people will evolve to chronic and 
recurrent LBP with socio-economic consequences such as work impairment and prolonged sick 
leaves (43). 
 
2.4.2 Back pain and Joint Hypermobility 
People with JH also experience low back pain. A study among musicians (44), as well as another 
study (45) among industrial workers, both showed that individuals with an hypermobile spine 
(hands flat on the floor) were more likely to suffer from back pain. An Iraqui study (28), showed 
that among hypemobile (Beighton) individuals with chondromalacia patella, after knee pain, LBP 
was the most frequent complain (52%).  
 
2.4.3 Back pain and Joint Hypermobility Syndrome 
Some studies have already linked JHS with back pain. An Indian study (46), assessing the 
relationship between posture and pain among people with JHS, showed that LBP was the third most 
frequent pain complaint among individuals with JHS. Grahame et al. (42), reported a strong 
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association between mechanical back pain and JHS in both sexes. Among Omani women attending 
physiotherapy in a hospital center (47), 63% of the ones presenting with LBP had JHS.  
The most similar paper to our study is the one from Howes et al. (48). It was a prospective study 
among 102 patients with back pain that also measured joint laxity. Since it was a study from 1971 
and the validated Beighton and Brighton criteria did not exist, other methods to assess laxity were 
used. Spine x-rays were taken and analysed. In this paper the «loose back syndrome» was described 
for the first time. They found a higher prevalence of spine hypermobility among individuals without 
an anatomical explanation (x-ray) for their back pain. This situation was even more frequent among 
women.  Pain had usually started in their teen years, was (invariabily) present in the low back and 
other joints were also hypermobile. 
 
2.4.4 Spine and Hypermobility 
A study from 1981 (26), in which spinal x-rays were analysed, showed a high prevalence (73%) of 
spinal anomalies like spondylolisthesis, pars interarticularis defect, transitional vertebrae at the 
lumbar sacral junction as well as scoliosis in the subgroup of people having a Beighton score of 5 
out of 9. 
A study from Bird et al. (49), looked at the link between spondylolisthesis and JH. Although they 
did not find a significant correlation, they still concluded that an association probably exists, and 
that spondylolisthesis probably is a consequence of back hyperlaxity. Moreover, spondylolisthesis 
as well as back pain (experienced for 3 months or longer) are part of the minor criteria used to 
diagnose JHS (24). 
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2.4.5 Back Pain in a Paediatric Population and Hypermobility 
As to the association between JH or JHS and back pain in a child and teenage population, study 
results are conflicting. Most found no correlation between JH and back pain, but they sometimes 
used a higher Beighton cut-off point than usual (6/9 instead of 4/9) (50-53). One study showed a 
positive association between JH and back pain (54) . As to JHS, one study among a paediatric 
rheumatology population (already diagnosed with JHS), reported that LBP was their second 
commonest complaint (20). 
 
3. Study Aim 
Recent epidemiological studies on JH and JHS rarely took into account LBP complaints. Only one 
old study mentioned previously (48) examined individuals with back pain and searched for JH. To 
our knowledge, no study has measured the prevalence of JH and JHS among a population suffering 
from chronic non specific low back pain using the actual validated criteria (Beighton and Brighton). 
Therefore, we aimed to ascertain the prevalence of JH and JHS in a male and female Swiss 
population presenting with non-specific chronic LBP. 
We hope to verify the following hypothesis: 
1. To find a higher prevalence of JH and JHS in our chronic LBP population than the one 
found in the general population. To find a similar or even higher prevalence of JH and JHS 
in our population than the one found in the literature in a general rheumatology population. 
2. Depending on the prevalence of JH and JHS we find, it could change the way in which we 
see and treat chronic LBP. 
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4.Material and Methods: 
4.1 Patients Recruitment 
A retrospective cross-sectional study based on a prospective database was conducted among 235 
patients seen at the specialised back pain unit at Lausanne University Hospital (Switzerland). Only 
files of patients that had come for the first time to the consultation between the periods of the 10th 
may 2009 to the 10th October 2010 were selected. All files were found either on paper or on 
electronic versions. 
 
4.2 Inclusion and Exclusion Criteria 
Only patients having non-specific chronic LBP (>4 3 months) as a main complaint and coming for 
the first time to the back consultation were included. The exclusion criteria were the following: not 
having LBP as the main complaint or insufficient data being available. For instance patients 
complaining mainly of cervicalgia, brachio-cervicalgia or sciatalgia were not included. 
 
4.3 Clinical Exam 
All patients were seen by the same rheumatology and spine specialist (PdG), who conducted a 
detailed and systematic medical and personal history with each patient. A precise clinical back 
exam, as well as a general laxity exam was performed. When available, spine MRI or X-rays were 
analysed. 
 
4.4 Patients History 
Precise medical and personal history as well as family history was obtained. Socio-economic 
information like working status, education level or insurance claims were also obtained. Special 
attention was given to indication of obstructive sleep disorder and signs of anxiety or depression.  
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4.5 Hypermobility Assessment 
Joint Hypermobility was assessed using the Beighton scoring system (6), considered positive when 
four or more out of the nine clinical points were present. Details of that scoring system are 
presented in Table 1 (previous pages). Since hypermobility signs decrease with age, for individuals 
being over fifty, the Hakim and Graham questionnaire (10) was also used additionally to the 
Brighton criteria. A positive questionnaire or an historical Beighton score of 4/9 was considered as 
having the same value as the clinical Beighton score in younger individuals (like it is accepted in 
the Brighton criteria) (24). Joint Hypermobility Syndrome was assessed using the 1998 revised 
Brighton criteria (cited before), presented on Table 2. 
 
4.6 Data 
Demographic and socio-economic data included sex, age, body mass index (BMI), marital status, 
education (primary, secondary, university), religion (Catholic, Protestant, other), origin (Swiss, 
other), employment category (Manual, non manual, half-manual), work status (full time, part time, 
off work/unemployed) and smoking status (non smoker, former smoker, smoker). Duration of LBP 
was defined as the time delay between symptoms occurrence and the date of the consultation with 
the specialist. Limitations in activities of daily living (ADL) was defined as the patient reporting 
any disturbances in all three following categories: house chores, driving or being a car passenger 
and sexual activity. Child abuse and neglect (CAN) was measured by taking detailed personal and 
familial anamnesis, using a genogram. Anxiety, depression, psychological diagnosis, possible 
microinstability1, degenerative spinal disorder2, health insurance conflict data were also collected.  
 
                                                
1 Here defined as sudden painful back spasme  revieled by medical history, type I , II  modifications 
and / or instability spondylophytes (according to the McNab X-Ray classification) 
2 Degenerative spinal disorders are here defined as spine arthrosis as well as disc herniations  
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4.7 Statistics 
The sample size calculation was based on a margin of error for the prevalence estimates of 8%. In 
the absence of data, the sample size was calculated for a conservative prevalence estimate of 0.5. A 
multiple logistic regression model was constructed by incorporating as independent variables age, 
sex, and only those with P<0.25 in the analysis. Data analysis was performed using Stata 11.0 (Stata 
Corporation, College Station, Texas, USA). The significance level was set at 0.05.  
 
4.8 Ethics 
Ethical approval for the study was granted by the Ethics Committee of the University Medical 
School of Lausanne (Switzerland). 
 
5.Results 
5.1 Baseline characteristics 
Of the 235 patients files from the selected period, 143 met the inclusion criteria and were 
statistically analysed. Table 3 presents baseline characteristics of the individuals included in the 
sample. Both genders were equally represented (70 women and 73 men). Thirty percent were older 
than 50 years. The majority of the individuals were married and catholic. About 53% had a Swiss 
origin and the rest were mostly Europeans, the second biggest origin group being people from 
Portugal (14%). The majority of patients had secondary education but did not go to University. 
Most patients had a manual profession. Despite their back pain, about 46% of the selected patients 
still worked full time on the day of the consultation. As to the duration of low back pain, a minority 
of patients had experienced it for less than a year (10,8%) but the majority of them had been 
suffering from it for more than 10 years (46,2%). 
 
 
 
 15 
Table 3. Subjects’ baseline characteristics. 
 
Variable n % 
Sex   
    Women 70 49.0 
    Men 73 51.0 
Age    
    < 40 years 49 34.3 
    40-50 years 51 35.7 
    > 50 years 43 30.0 
BMI   
    Underweight 4 2.8 
    Normal weight 58 40.6 
    Overweight 48 33.6 
    Obesity 33 23.1 
Marital status   
    Single 39 27.5 
    Married 64 45.1 
    Divorced/Widowed 39 27.5 
Education   
    Primary 42 32.3 
    Secondary 55 42.3 
    University 33 25.4 
Religion   
    Catholic 59        49.2 
    Protestant 33        27.5 
    Other 28        23.3 
Origin   
    Swiss 74        52.9 
    Other 66        47.1 
Employment category   
    Non-manual 37 26.8 
    Manual 69 50.0 
    Half manual/half non-manual 32 23.2 
Work status   
    Full time 59 45.7 
    Part time 27 20.9 
    Off work / unemployed 43 33.3 
Smoking   
    Non smoker 52 36.9 
    Former smoker 34 24.1 
    Smoker 55 39.0 
LBP duration   
    < 1 year 14 10.8 
    1-5 years 33 25.4 
    5-10 years 23 17.7 
    > 10 years 60 46.2 
BMI = body mass index ; LBP = low back pain 
 
 16 
5.2 Univariate analyses 
Table 4 shows JH and JHS prevalence according to socio-economic and demographic 
characteristics. In both conditions, the prevalence was slightly higher among women than among 
men. JH was found in 33.3% of women (confidence interval 22.0-44.6) and in 21.4% (11.7-31.2) of 
men. JHS was found in 37.9% (26.0-49.8) of women and 30.9% (19.7-42.0) of men. Clinical JH 
(Beighton score) was significantly less prevalent (P < 0.02) among people older than 50 years.  
 
Another significant result (P < 0.01) is the fact that JHS was more prevalent in Swiss individuals 
than in individuals of other origins. There also was a positive correlation (P < 0.03) between having 
a non-manual job and the prevalence of the JHS.  
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Table 4. Joint hypermobility prevalence and joint hypermobility syndrome prevalence according 
to socioeconomic and demographic characteristics. 
 JH prevalence  JHS prevalence 
Variable n % (95% CI) OR (95%CI) P*  n % (95% CI) OR (95%CI) P* 
Total 139 27.3 (19.8-34.8)    122  34.3 (26.2-42.5)   
Sex §         
    Women 69  33.3 (22.0-44.6)  1.00   66 37.9 (26.0-49.8)  1.00  
    Men 70  21.4 (11.7-31.2)  0.48 (0.22-1.05) 0.066  68 30.9 (19.7-42.0)  0.68 (0.33-1.42) 0.305 
Age ¶         
    < 40 years 47  34.0 (20.2-47.9)  1.00    47  40.4 (26.1-54.7)  1.00  
    40-50 years 50  32.0 (18.8-45.2)  0.87 (0.37-2.06) 0.753  46  34.8 (20.7-48.8)  0.77 (0.33-1.79) 0.541 
    > 50 years 42  14.3 (3.5-25.1)  0.28 (0.09-0.81) 0.020  41  26.8 (13.0-40.7)  0.51 (0.20-1.26) 0.145 
BMI         
    Underweight 4  50.0 (-7.1-107.1)  1.54 (0.19-12.59) 0.683  4  50.0 (-7.1-107.1)  2.07 (0.26-16.44) 
0.492 
    Normal weight 57  36.8 (24.1-49.6)  1.00   56  30.4 (18.1-42.6)  1.00  
    Overweight 47  19.1 (7.7-30.6)  0.59 (0.22-1.54) 0.278  45  35.6 (21.3-49.8)  1.67 (0.68-4.06) 0.262 
    Obesity 31  19.4 (5.1-33.6)  0.49 (0.17-1.45) 0.198  29  37.9 (19.8-56.1)  1.60 (0.61-4.21) 0.343 
Marital status         
    Single 37  35.1 (19.4-50.9)  1.00   36  38.9 (22.6-55.2)  1.00  
    Married 62  22.6 (12.0-33.2)  1.26 (0.42-3.74) 0.676  61  32.8 (20.8-44.8)  1.14 (0.42-3.09) 0.798 
    Divorced/Widowed 39  28.2 (13.8-42.6)  2.06 (0.57-7.43) 0.269  36  33.3 (17.6-49.1)  1.26 (0.38-4.12) 0.708 
Education         
    Primary 40  22.5 (9.3-35.7)  1.00   39  25.6 (11.6-39.7)  1.00  
    Secondary 55  25.5 (13.7-37.2)  1.03 (0.38-2.84) 0.947  50  38.0 (24.3-51.7)  1.67 (0.66-4.24) 0.283 
    University 32  40.6 (23.2-58.1)  2.66 (0.91-7.81) 0.075  32  43.8 (26.1-61.4)  2.25 (0.81-6.22) 0.118 
Religion         
    Catholic 58  22.4 (11.5-33.4)  1.00   56  35.7 (22.9-48.5)  1.00  
    Protestant 33  30.3 (14.2-46.4)  1.70 (0.61-4.73) 0.312  32  40.6 (23.1-58.1)  1.31 (0.52-3.29) 0.567 
    Other 25  28.0 (9.8-46.2)  1.50 (0.49-4.56) 0.478  24  25.0 (7.1-42.9)  0.62 (0.21-1.83) 0.384 
Origin         
    Swiss 72  33.3 (22.3-44.4)  1.00   71  43.7 (31.9-55.4)  1.00  
    Other 64  21.9 (11.6-32.2)  0.51 (0.23-1.15) 0.103  60  23.3 (12.4-34.2)  0.37 (0.17-0.80) 0.011 
Employment category         
    Manual 67 23.9 (13.5-34.3)  1.00   64  28.1 (16.9-39.3)  1.00  
    Non-manual 37  35.1 (19.4-50.9)  2.00 (0.78-5.12) 0.149  36  50.0 (33.3-66.7)  2.71 (1.13-6.54) 0.026 
    Half manual/half  
    non-manual 
30  26.7 (10.4-42.9)  1.37 (0.46-4.04) 0.568  30  30.0 (13.2-46.8)  1.16 (0.43-3.14) 0.771 
Work status          
    Full time 58  27.6 (15.9-39.3)  1.00   57  35.1 (22.5-47.7)  1.00  
    Part time 26  38.5 (19.2-57.7)  1.80 (0.64-5.10) 0.265  26  34.6 (15.8-53.5)  1.02 (0.37-2.78) 0.970 
    Off work /  
    unemployed 
42  21.4 (8.7-34.1)  0.80 (0.30-2.14) 0.657  38  34.2 (18.8-49.7)  1.04 (0.43-2.54) 0.929 
Smoking         
    Non smoker 50  32.0 (18.8-45.2)  1.00   52  25.0 (13.0-37.0)  1.00  
    Former smoker 33  21.2 (6.9-35.5)  0.74 (0.25-2.18) 0.586  30  43.3 (25.1-61.5)  2.94 (1.07-8.04) 0.036 
    Smoker 54  25.9 (14.0-37.8)  0.68 (0.27-1.68) 0.400  50  38.0 (24.3-51.7)  1.84 (0.76-4.45) 0.176 
JH = joint hypermobility; JHS = joint hypermobility syndrome; CI = confidence interval; OR = odds ratio, adjusted for age and sex; 
*Pearson’s Chi-square test, adjusted for age and sex ; § = adjusted only to age; ¶ = adjusted only to sex; BMI = body mass index 
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Table 5 presents JH and JHS prevalence according to clinical characteristics. About 60% of the 
patients with JH and 85% of patients with JHS had been experiencing back pain for at least more 
than five years. The most significant result is the association between JH and degenerative spinal 
disorders. Among patients without degenerative spinal disorders, there was a higher prevalence of 
JH (46.8%, CI 32.2-61.3) and of JHS (54.5%, CI 39.5-69.6) than in patients with degenerative 
spinal disorders, with the following OR and p values: (OR 0.31, P < 0.007) for JH and (OR 0.31, P 
< 0.004) for JHS. 
Table 5. Joint hypermobility prevalence and joint hypermobility syndrome prevalence according 
to clinical characteristics. 
 JH prevalence  JHS prevalence 
Variable n % (95% CI) OR (95%CI) P*  n % (95% CI) OR (95%CI) P* 
Total 139 27.3 (19.8-34.8)    122  34.3 (26.2-42.5)   
LBP duration         
    < 1 year 14  21.4 (-1.1-44.0)  1.00   12  16.7 (-5.6-38.9)  1.00  
    1-5 years 31  22.6 (7.4-37.7)  1.14 (0.23-5.63) 0.871  32  25.0 (9.6-40.4)  1.75 (0.31-9.96) 0.528 
    5-10 years 22  31.8 (11.7-51.9)  1.66 (0.32-8.55) 0.546  21  47.6 (25.5-69.7)  4.82 (0.81-28.70) 0.084 
    > 10 years 59  28.8 (17.0-40.6)  2.06 (.046-9.34) 0.346  56  37.5 (24.6-50.4)  3.74 (0.70-19.84) 0.121 
Health insurance conflict         
    Yes 8  12.5 (-12.2-37.2)  0.57 (0.06-5.07) 0.612  8  25.0 (-7.4-57.4)  0.84 (0.15-4.53) 0.836 
    No 128  27.3 (19.5-35.2)  1.00   122  34.4 (25.9-43.0)  1.00  
Microinstability         
    Yes 96  27.1 (18.1-36.1)  0.95 (0.41-2.20) 0.898  93  35.5 (25.6-45.4)  1.18 (0.53-2.62) 0.688 
    No 43  27.9 (14.2-41.6)  1.00   41  31.7 (17.2-46.3)  1.00  
Degenerative spinal 
disorder 
        
    Yes 88  17.0 (9.1-25.0)  0.31 (0.13-0.73) 0.007  85  24.7 (15.4-34.0)  0.31 (0.14-0.68) 0.004 
    No 47  46.8 (32.2-61.3)  1.00   44  54.5 (39.5-69.6)  1.00  
Anxiety         
    Yes 32  25.0 (9.6-40.4)  0.84 (0.32-2.22) 0.725  31  35.5 (18.2-52.8)  1.09 (0.45-2.63) 0.852 
    No 89  28.1 (18.6-37.6)  1.00   86  34.9 (24.6-45.1)  1.00  
Depression         
    Yes 45  26.7 (13.5-39.9)  1.14 (0.47-2.72) 0.775  44  31.8 (17.7-45.9)  0.85 (0.38-1.90) 0.691 
    No 76  27.6 (17.4-37.9)  1.00   73  37.0 (25.7-48.3)  1.00  
Psychological diagnosis         
    Yes 16  18.8 (-1.2-38.7)  0.60 (0.15-2.34) 0.464  17  23.5 (2.5-44.5)  0.53 (0.16-1.75) 0.296 
    No 107  28.0 (19.4-36.7)  1.00   101  36.6 (27.1-46.2)  1.00  
CAN         
    Yes 29  31.0 (13.7-48.3)  1.11 (0.42-2.95) 0.827  28  39.3 (20.7-57.9)  1.17 (0.47-2.89) 0.735 
    No 98  27.6 (18.6-36.5)  1.00   95  34.7 (25.0-44.4)  1.00  
ADL limitations         
    Yes 67  31.3 (20.0-42.7)  1.85 (0.72-4.72) 0.199  64  39.1 (26.9-51.2)  2.01 (0.84-4.78) 0.114 
    No 45  20.0 (8.1-31.9)  1.00   45  24.4 (11.6-37.3)  1.00  
JH = joint hypermobility; JHS = joint hypermobility syndrome; CI = confidence interval; OR = odds ratio, adjusted for age and sex; 
*Pearson’s Chi-square test, adjusted for age and sex; LBP = low back pain; CAN = child abuse and neglect; ADL = activities of 
daily living 
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Table 6 presents multiple logistic regression analysis for JH and JHS according to socio-economic, 
demographic and clinical characteristics. The association between JH (OR 0.25, P < 0.011) and JHS 
(OR 0.17, P < 0.006) and degenerative spinal disorders was confirmed again. Individuals having an 
important limitation for ADL are four times more likely to have JHS than individuals having low 
back pain but experiencing less ADL limitations. According to our results patients being older than 
50 years of age are less likely to be diagnosed with JH (OR 0.18, P < 0.030) and JHS (OR 0.11, P < 
0.019) than younger individuals. 
 
Table 6. Multiple logistic regression analysis for joint hypermobility and joint hypermobility 
syndrome according to socioeconomic, demographic and clinical characteristics. 
 
 JH (n = 98)  JHS (n = 85) 
Variable OR (95%CI) P*  OR (95%CI) P*  
Sex     
    Men  0.53 (0.20-1.44) 0.212   1.30 (0.41-4.07) 0.655 
Age     
    > 50 years  0.18 (0.04-0.85) 0.030   0.11 (0.02-0.70) 0.019 
BMI     
    Obesity  1.09 (0.31-3.90) 0.890     
Education     
    University  1.13 (0.29-4.37) 0.859   1.12 (0.26-4.91) 0.880 
Origin     
    Other  0.77 (0.26-2.28) 0.635   0.77 (0.21-2.78) 0.687 
Employment category     
    Non-manual  2.92 (0.71-11.96) 0.136   3.27 (0.66-16.25) 0.147 
Smoking     
    Former smoker     0.69 (0.14-3.30) 0.643 
    Smoker     1.83 (0.54-6.27) 0.335 
LBP duration     
    5-10 years      3.68 (0.76-17.88) 0.106 
    > 10 years      3.24 (0.72-14.55) 0.125 
Degenerative spinal disorder     
    Yes  0.25 (0.09-0.73) 0.011   0.17 (0.05-0.60) 0.006 
ADL limitations     
    Yes  2.36 (0.82-6.82) 0.113   4.18 (1.23-14.14) 0.022 
JH = joint hypermobility; JHS = joint hypermobility syndrome; OR = odds ratio; CI = confidence interval; *Pearson’s Chi-square test; 
BMI = body mass index; LBP = low back pain; ADL = activities of daily living 
 
 20 
6.Discussion 
The main purpose of this study was to ascertain the prevalence of JH and JHS in a population 
suffering from chronic non-specific LBP and determine if JH and JHS are more frequent in certain 
subgroups of patients. We found a high prevalence of JH and JHS in our population. Among 
women, we found a prevalence of 33,3% for JH and of 37,9% for JHS. Among men, we found a 
prevalence of 21,4% for JH and of 30,9% for JHS. Our most significant result was the negative 
association between JH or JHS and degenerative spinal disorders. In our population, patients having 
degenerative spinal disorders were less likely to have JHS. We also found that individuals older 
than 50 years of age were less likely to be diagnosed with JH and JHS.  
LBP of individuals having JH or JHS seams to last longer than LBP of individuals without JH or 
JHS. This observation can be considered as clinically important even though it did not reach 
statistical significance. These are all new information,  since, to our knowledge, no recent studies 
have looked at JHS in individuals presenting LBP with the current validated criteria. 
 
The non-randomized and retrospective nature of this study limits the conclusions that can be drawn 
from the data. However,data were prospectively collected by a single experimented rheumatology 
and back specialist (PdG) through a classical back consultation that systematically included JH and 
JHS diagnostic tests, thereby limiting potential bias. The prevalence of JHS is currently unknown in 
the Swiss or European general population so that no comparisons are possible. Also, imaging exams 
were not performed among all patients, which can influence the prevalence of degenerative spinal 
disorders. These limitations are counterbalanced by a rigourous methodology that enabled view 
missing data. Indeed, all positive diagnosis were verified by the rheumatologist and a second person 
(IC) by carefully analysing each patient’s file.  
The prevalence of JHS in a general Western or Swiss population is currently unknown but we can 
compare our results with the JHS prevalence in general rheumatology clinics. In 2004 Graham et al. 
(42) reported a JHS prevalence of 46% among women and 31% among men (England), which is 
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similar to our results (37,9% for women and 30,9% for men). We even found a higher prevalence of 
JH in our LBP population than Guma et al. (55) in their Spanish general rheumatology population 
(25%). We found a smaller prevalence of JHS than Clark et al. (47) found in their Omani female 
population (55%). Maybe Omani people are more likely to have JH and JHS, since we already 
know that ethnic variation exist. Also, we can say that the population of this study is not 
comparable to ours, since it consists exclusively of female patients, referred by orthopaedic 
surgeons to attend physiotherapy (and not a two gender rheumatology population like ours). 
The prevalence of simple JH is estimated as high as 10% in a Western general population, which is 
two to three times less than the prevalence we found in our population (33,3% for women and 
21,4% for men). Our results also confirm the general knowledge that JH is more frequent among 
women and that clinical signs of hypermobility diminish with age (4, 56). Since in this study we 
considered the questionnaire (10) or the anamnestic Beighton as having the same value as the 
clinical Beighton in patients older than 50, it is surprising that despite this precaution, we also found 
that JHS was less frequent at that age range. It might be explained by the fact that some patients are 
unaware of their own hypermobility as well as by memory bias. 
As to the negative association between JH and JHS with degenerative spinal disorders, it can be 
surprising since degenerative spine disorders like spondylolisthesis are part of the diagnose criteria 
for JHS and should to be favoured by back laxity. On the other hand, our result are in accordance 
with the findings of Howes et al. (48). Indeed, for them the «loose back syndrome» was more 
frequent among individuals without anatomical findings on the spine x-ray. Also, in our study, 
imaging of the back was not available for all patients. Results might have been different if that was 
the case. 
Even if it is not a significant association, it is interesting to discuss the fact that JH and JHS was 
more frequent among individuals having a non-manual job as well as people with a Swiss origin. 
We can easily imagine, that individuals with a manual job even without JH are still at greater risk of 
having mechanical LBP secondary to their heavy work. Also, even thought there is little data 
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available on the subject, there is a study from 1971 (56) that reported that children belonging to the 
higher income group were more lax jointed than those of the lower social classes. As non-manual 
jobs are the ones achieved by higher education and allowing for a higher income, this could be the 
first small step to a possible explanation for this result.  
As to the racial prevalence disparity, it may be due to genetical differences since JHS is an inherited 
condition. Also, the two characteristics may reinforce each other, since non-Swiss individuals are 
more likely to work in the manufacturing sector than the service sector compared to Swiss 
individuals.3 
                                                
3 Swiss Federal Office of Statistics (homepage on the internet). Bern. Available from 
http://www.bfs.admin.ch 
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7. Conclusion: 
In our Swiss population with chronic non-specific LBP, the prevalence of JH was higher than the 
one found in the general western population (around 10%) (5) and than the one found in a 
rheumatolgy clinic in Spain (55) . We also found a high prevalence of JHS, comparable to the one 
found in a general rheumatology clinic in England (42). 
Therefore, we can only stress the importance for doctors to search for JH and JHS using the 
validated criteria (Beighton and Brighton), as well as the validated four item questionnaire from 
Hakim and Grahame in their daily practice. Especially when facing patients with unexplained 
chronic pain, including LBP. 
A 2001 study from Graham et al. (57) showed that JHS was not well known even by rheumatology 
specialists. It is therefore not surprising that JHS is an under-diagnosed condition, only 1/20 people 
with JHS having the correct diagnosis (58). 
Other studies (59-63), show that, in adults as well as in children, individuals with fibromyalgia 
syndrome (FMS) and chronic fatigue syndrome (CFS) have a higher prevalence of JH and JHS. 
For all those reasons, we support another authors opinion (17, 64), that it is important to consider 
JHS when or even before making the diagnosis of FMS or CFS.  
Like other authors (16, 57), we think it is important to make doctors more aware of JHS. This effort 
should be made for different reasons.  
First of all, for our patients benefit. Indeed like it is reported in the literature, living with JHS, 
especially without having been diagnosed is “painfull” (58, 65). Sometimes patients even start 
doubting themselves and to believe that the symptoms are only psychological (66). A recent study 
(67) even showed that female patients with EDS hypermobile type (comparable to JHS) even suffer 
from a greater burden than the ones having rheumaroid arthritis. Also, it usually takes about 10 
years for the diagnosis to be made (68), and it is received with relief (66).  
 
 24 
Beeing aware of and diagnosing JHS is also important for our public health system. Indeed, in 
2005, LBP was the most prevalent health problem in Switzerland and was responsible for 6,1% of 
the total health care costs (69). Since classical treatments are ineffective or can even make the 
situation worse in individuals with JHS (4), diagnosing the subgroup of people having LBP 
secondary to JH is crucial. It means being able to give them appropriate treatment (4, 41, 46, 68) 
and help them recover. Early recognition and treatment prevents pain from becoming chronic and 
even more difficult to manage. It can also avoid work absenteeism, presenteism and their associated 
social consequences. 
 
Is it not our duty as doctors, or future doctors, to avoid being so «fascinated» by fancy technologies 
and complicated diagnosis, that we forget simple clinical diagnosis which can have such a big 
impact on people’s lives and public health?  
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